RVMD — Revolution Medicines, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1628171 ·
Last close
$182.08
Market Cap
$38.71B
52W High
$184.39
52W Low
$91.52
ADV30
3,190,170
Next earnings
2026-08-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -445,222,000 | -453,816,000 | 2,253,737,000 | 440,939,000 | 753,820,000 |
| Dec 2025 | 0 | — | -361,626,000 | -364,892,000 | 2,354,508,000 | 383,745,000 | 723,211,000 |
| Sep 2025 | 0 | — | -315,269,000 | -305,206,000 | 2,251,920,000 | 217,442,000 | 655,016,000 |
| Jun 2025 | 0 | — | -264,714,000 | -247,787,000 | 2,429,568,000 | 402,438,000 | 564,199,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-897,741,000
Investing CF
$118,058,000
Financing CF
$621,524,000
CapEx
$-15,990,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-5.91
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-2,869,102,000
Inventory
—
Receivables
—
ST Investments
$1,641,934,000
EBIT TTM
$-1,152,208,000
Pretax Income TTM
$-1,131,301,000
Interest Exp TTM
$23,364,000
Analysts
20
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -1,182,369,000 | -1,131,301,000 | 2,354,508,000 | 723,211,000 | — | -897,741,000 |
| Dec 2024 | 0 | -689,524,000 | -600,093,000 | 2,558,301,000 | 293,097,000 | — | -557,436,000 |
| Dec 2023 | 11,580,000 | -487,185,000 | -436,367,000 | 2,061,705,000 | 235,511,000 | — | -350,572,000 |
| Dec 2022 | 35,380,000 | -258,279,000 | -248,705,000 | 811,930,000 | 126,742,000 | — | -224,401,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-5.70
Max Pain — expiry 2026-07-17
max pain strike: $155.00 · spot: $186.25 · call oi: 12,639 · put oi: 3,599
Expected Move to 2026-07-17:
±$16.75
(8.99%) —
implied range
$169.50 –
$203.00
· ATM straddle on $185.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| BIIB | BIOGEN INC. | $31.89B | $216.03 | — |
| ARGX | ARGENX SE | $55.17B | $887.18 | — |
| MRNA | Moderna, Inc. | $26.69B | $67.27 | — |
| BNTX | BioNTech SE | $23.07B | $91.22 | — |
| NBIX | NEUROCRINE BIOSCIENCES INC | $16.94B | $168.52 | — |
News headlines (Yahoo Finance, 1h cache)
This Biotech ETF Has Almost Doubled in 13 Months. Money Is Flowing In.
2026-06-26 19:38 · Yahoo
FDA accepts Replimune filing; Merck KGaA drops $11B on life sciences services
2026-06-26 11:53 · Yahoo
Revolution Medicines to Present Clinical Data from RAS(ON) Inhibitor Combination Trials in Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026
2026-06-24 23:31 · Yahoo
RVMD Starts Treatment in Phase III Pancreatic Cancer Study on Zoldonrasib
2026-06-24 14:13 · Yahoo
After Apogee, 3 More Biotech Buyout Targets Wall Street Can’t Stop Watching
2026-06-24 11:55 · Yahoo
Revolution Medicines Begins Treating Patients in RASolute 305, a Phase 3 Clinical Trial Evaluating Zoldonrasib in Combination with Chemotherapy as a First Line Treatment for Patients with RAS G12D Met
2026-06-23 12:00 · Yahoo
Revolution Medicines Announces Planned Leadership Transition for Steve Kelsey, M.D.
2026-06-22 12:00 · Yahoo
Pancreatic Cancer Drug Milestone Affirms Why Revolution Medicines Inc. (RVMD) is a Hot Stock to Buy
2026-06-13 19:30 · Yahoo
Daraxonrasib’s Phase 3 Pancreatic Cancer Survival Data Might Change The Case For Investing In RVMD
2026-06-12 00:23 · Yahoo
Can Revolution Medicines Be a Game-Changer Stock?
2026-06-11 11:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.